Shire (LSE:SHP) Accounts Payable : £3,079 Mil (As of Sep. 2018)

View and export this data going back to 1996. Start your Free Trial

What is Shire Accounts Payable?

Shire's Accounts Payable for the quarter that ended in Sep. 2018 was £3,079 Mil.

Shire's quarterly Accounts Payable increased from Mar. 2018 (£2,820 Mil) to Jun. 2018 (£2,924 Mil) and increased from Jun. 2018 (£2,924 Mil) to Sep. 2018 (£3,079 Mil).

Shire's annual Accounts Payable increased from Dec. 2015 (£295 Mil) to Dec. 2016 (£730 Mil) but then declined from Dec. 2016 (£730 Mil) to Dec. 2017 (£682 Mil).

Shire Accounts Payable Historical Data

The historical data trend for Shire's Accounts Payable can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Shire Accounts Payable Chart

Shire Annual Data

Trend

Dec08

Dec09

Dec10

Dec11

Dec12

Dec13

Dec14

Dec15

Dec16

Dec17

Accounts Payable

Get a 7-Day Free Trial

123.59

158.28

294.86

730.43

682.29

Shire Quarterly Data
	Dec13	Mar14	Jun14	Sep14	Dec14	Mar15	Jun15	Sep15	Dec15	Mar16	Jun16	Sep16	Dec16	Mar17	Jun17	Sep17	Dec17	Mar18	Jun18	Sep18
Accounts Payable	Get a 7-Day Free Trial															2,902.88	682.29	2,820.32	2,924.15	3,079.20

Shire Accounts Payable Calculation

Accounts Payable represents any money that a company owes its suppliers for goods and services purchased on credit and is expected to pay within the next year or operating cycle.

Shire Accounts Payable Related Terms

Thank you for viewing the detailed overview of Shire's Accounts Payable provided by GuruFocus.com. Please click on the following links to see related term pages.

Shire (LSE:SHP) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Shire PLC (LSE:SHP) » Definitions » Accounts Payable

Comparable Companies

Traded in Other Exchanges

N/A

Address

Website

http://www.shire.com

Shire is a diversified, Ireland-based specialty drug firm. Shire has grown primarily through mergers and acquisitions, including the Transkaryotic Therapies acquisition in 2005, which established its genetic disease business with Replagal and Elaprase, and the merger with New River in 2007, which brought full rights to neuroscience drug Vyvanse. Shire completed the acquisition of ViroPharma (genetic diseases) in 2014, NPS Pharma (internal medicine) in 2015, and Baxalta (hematology, immunology, and oncology) and Dyax (genetic diseases) in 2016.

Shire (LSE:SHP) Headlines

No Headlines